HYBRID EVENT: You can participate in person at Tokyo, Japan from your home or work.
Cancer vaccines represent a groundbreaking frontier in cancer immunotherapy, aiming to harness the body's immune system to recognize and destroy cancer cells. Unlike traditional vaccines that prevent infectious diseases, cancer vaccines are designed to stimulate an immune response specifically against cancer cells. These vaccines work by introducing antigens, which are substances that trigger an immune response, associated with cancer cells. The goal is to prime the immune system to recognize and target these specific antigens, leading to a more targeted and effective immune response against cancer.
There are different types of cancer vaccines, including preventive vaccines and therapeutic vaccines. Preventive vaccines are aimed at preventing certain types of cancer by targeting infectious agents known to increase cancer risk, such as human papillomavirus (HPV) or hepatitis B virus (HBV). Therapeutic cancer vaccines, on the other hand, are developed to treat existing cancers by training the immune system to recognize and attack cancer cells. These vaccines often incorporate cancer-specific antigens, encouraging the immune system to mount a targeted attack against the malignant cells. While cancer vaccines have shown promise, it's important to note that they are still an area of active research, and their effectiveness can vary based on the type of cancer and individual patient factors.
Cancer vaccine research faces challenges, including the complexity of the immune response and the ability of cancer cells to evade detection. Additionally, the development of personalized cancer vaccines, tailored to an individual's unique tumor profile, is an exciting area of exploration. Advances in understanding the tumor microenvironment, immune checkpoint inhibitors, and combination therapies further contribute to the evolving landscape of cancer vaccines.
